Alnylam Pharmace. buy TD Cowen
Start price
21.10.24
/
50%
€269.00
Target price
21.10.25
€341.77
Performance (%)
50.93%
End price
22.10.25
€406.00
Summary
This prediction ended on 22.10.25 with a price of €406.00. With a performance of 50.93% the BUY prediction by TD_Cowen was a big success. TD_Cowen has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 7.220% | 7.220% | -47.180% |
| iShares Core DAX® | -1.059% | 5.007% | 6.596% |
| iShares Nasdaq 100 | -2.387% | 0.864% | 25.791% |
| iShares Nikkei 225® | -4.361% | 1.211% | 41.309% |
| iShares S&P 500 | -1.778% | 1.391% | 21.037% |
Comments by TD_Cowen for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at TD Cowen from $282.00 to $371.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von TD_Cowen gewählte maximale Laufzeit wurde überschritten
Stopped prediction by TD_Cowen for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€222.10
25.06.24
25.06.24
€263.30
25.06.25
25.06.25
25.12%
26.06.25
26.06.25
